Last reviewed 2026-04-22 · How we verify

Norethindrone acetate (NTA)

Baylor Research Institute · FDA-approved active Small molecule

Norethindrone acetate (NTA) is a Progestin Small molecule drug developed by Baylor Research Institute. It is currently FDA-approved for Oral contraception, Endometriosis, Abnormal uterine bleeding.

Norethindrone acetate is a synthetic progestin that binds to progesterone receptors to suppress ovulation and alter the endometrium for contraceptive and hormonal therapy effects.

Norethindrone acetate is a synthetic progestin that binds to progesterone receptors to suppress ovulation and alter the endometrium for contraceptive and hormonal therapeutic effects. Used for Oral contraception, Endometriosis, Abnormal uterine bleeding.

At a glance

Generic name	Norethindrone acetate (NTA)
Sponsor	Baylor Research Institute
Drug class	Progestin
Target	Progesterone receptor
Modality	Small molecule
Therapeutic area	Contraception, Gynecology, Endocrinology
Phase	FDA-approved

Mechanism of action

As a progestin, norethindrone acetate acts primarily on progesterone receptors in the hypothalamus and pituitary gland to inhibit the luteinizing hormone (LH) surge, thereby preventing ovulation. It also thickens cervical mucus and alters the endometrial lining to create an inhospitable environment for sperm and embryo implantation. These combined effects make it effective for contraception and management of hormone-dependent conditions.

Approved indications

Oral contraception
Endometriosis
Abnormal uterine bleeding
Hormone replacement therapy

Common side effects

Nausea
Headache
Breast tenderness
Irregular bleeding
Weight changes
Mood changes

Key clinical trials

Effects of a Progestin on Frequent and/or Prolonged Bleeding With Nexplanon™ (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Norethindrone acetate (NTA) CI brief — competitive landscape report
Norethindrone acetate (NTA) updates RSS · CI watch RSS
Baylor Research Institute portfolio CI

Frequently asked questions about Norethindrone acetate (NTA)

What is Norethindrone acetate (NTA)?

Norethindrone acetate (NTA) is a Progestin drug developed by Baylor Research Institute, indicated for Oral contraception, Endometriosis, Abnormal uterine bleeding.

How does Norethindrone acetate (NTA) work?

Norethindrone acetate is a synthetic progestin that binds to progesterone receptors to suppress ovulation and alter the endometrium for contraceptive and hormonal therapy effects.

What is Norethindrone acetate (NTA) used for?

Norethindrone acetate (NTA) is indicated for Oral contraception, Endometriosis, Abnormal uterine bleeding, Hormone replacement therapy.

Who makes Norethindrone acetate (NTA)?

Norethindrone acetate (NTA) is developed and marketed by Baylor Research Institute (see full Baylor Research Institute pipeline at /company/baylor-research-institute).

What drug class is Norethindrone acetate (NTA) in?

Norethindrone acetate (NTA) belongs to the Progestin class. See all Progestin drugs at /class/progestin.

What development phase is Norethindrone acetate (NTA) in?

Norethindrone acetate (NTA) is FDA-approved (marketed).

What are the side effects of Norethindrone acetate (NTA)?

Common side effects of Norethindrone acetate (NTA) include Nausea, Headache, Breast tenderness, Irregular bleeding, Weight changes, Mood changes.

What does Norethindrone acetate (NTA) target?

Norethindrone acetate (NTA) targets Progesterone receptor and is a Progestin.

Drug class: All Progestin drugs
Target: All drugs targeting Progesterone receptor
Manufacturer: Baylor Research Institute — full pipeline
Therapeutic area: All drugs in Contraception, Gynecology, Endocrinology
Indication: Drugs for Oral contraception
Indication: Drugs for Endometriosis
Indication: Drugs for Abnormal uterine bleeding

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing